Matthew D Galsky MD

Clinical Trials

• A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11

  Completed

  Phase 1

• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

  COMPLETED

  PHASE1, PHASE2

• Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Start of enrollment: 2010 Jun 01

  Withdrawn

  Phase 2

• First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01

  Terminated

  Phase 2

• Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Start of enrollment: 2011 Feb 01

  Terminated

  Phase 2

• Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma Start of enrollment: 2011 Mar 01

  Terminated

  Phase 1, Phase 2

• First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01

  Completed

  Phase 2

• A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01

  Terminated

  Phase 2

• Abiraterone Acetate Trial in African American Prostate Cancer Patients Start of enrollment: 2012 Dec 01

  Terminated

  Phase 2

• Immune Monitoring on Sipuleucel-T Start of enrollment: 2012 Jun 01

  Completed

• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Start of enrollment: 2015 Nov 11

  Completed

  Phase 2

• Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Start of enrollment: 2019 May 08

  Completed

  Phase 1

• Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Start of enrollment: 2018 Apr 17

  Completed

  Phase 2

• Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Start of enrollment: 2018 May 10

  Completed

  Phase 2

• Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Start of enrollment: 2018 Nov 12

  COMPLETED

  PHASE2

• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing Start of enrollment: 2018 Jul 13

  COMPLETED

  PHASE2

• Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17

  COMPLETED

  PHASE1

• Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations Start of enrollment: 2019 Jun 21

  Completed

  Phase 1

  Roles: Principal Investigator, Contact

• Pembrolizumab in Muscle-invasive Bladder Cancer Start of enrollment: 2022 Jul 13

  ACTIVE_NOT_RECRUITING

  PHASE2

  Roles: Sponsor-Investigator, Contact, Principal Investigator

• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Start of enrollment: 2023 Sep 22

  RECRUITING

  PHASE3

  Roles: Principal Investigator, Contact

• Join now to see all